Porkka, Kimmo

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 2,945

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 2,900

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Porkka, K., Koskenvesa, P., Lundán, T., Rimpiläinen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., Arnan, M., Brethon, B., et al. (2008) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 445

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Pemovska, T., Johnson, E., Kontro, M., Repasky, G. A., Chen, J., Wells, P., Cronin, C. N., McTigue, M., Kallioniemi, O., Porkka, K., et al. (2015) · Nature

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 234

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

Malani, D., Kumar, A., Brück, O., Kontro, M., Yadav, B., Hellesøy, M., Kuusanmäki, H., Dufva, O., Kankainen, M., Eldfors, S., et al. (2022) · Cancer Discovery

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 193

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia

Kuusanmäki, H., Leppä, A.-M., Pölönen, P., Kontro, M., Dufva, O., Deb, D., Yadav, B., Brück, O., Kumar, A., Everaus, H., et al. (2020) · Haematologica

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 186

IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models

Ågerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 98

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Adnan Awad, S., Kankainen, M., Ojala, T., Koskenvesa, P., Eldfors, S., Ghimire, B., Kumar, A., Kytölä, S., Kamel, M. M., Heckman, C. A., et al. (2020) · Blood Advances

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 67

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

Pietarinen, P. O., Pemovska, T., Kontro, M., Yadav, B., Mpindi, J. P., Andersson, E. I., Majumder, M. M., Kuusanmäki, H., Koskenvesa, P., Kallioniemi, O., et al. (2015) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 25

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Pietarinen, P. O., Eide, C. A., Ayuda-Durán, P., Potdar, S., Kuusanmäki, H., Andersson, E. I., Mpindi, J. P., Pemovska, T., Kontro, M., Heckman, C. A., et al. (2017) · Oncotarget

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16

Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia

Adnan Awad, S., Dufva, O., Klievink, J., Karjalainen, E., Ianevski, A., Pietarinen, P., Kim, D., Potdar, S., Wolf, M., Lotfi, K., et al. (2024) · Cell Reports Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 14